Skip to main
DRIO

DarioHealth (DRIO) Stock Forecast & Price Target

DarioHealth (DRIO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

DarioHealth is a virtual chronic care company that has shown sequential growth in revenue driven by channel partner traction and expansion into musculoskeletal conditions. The company aims to reach break-even cash flow by 4Q26/1Q27, which is reasonable given their focus on cost management and potential new partnerships with hospital systems. However, challenges such as limited growth visibility, potential churn of customers, and the need for further capital raises may hinder their revenue growth and profitability.

Bears say

DarioHealth is performing well in terms of revenue, with a 1Q revenue of $5.6M that beat the estimated $5.3M, driven by strong B2C revenue from MSK solutions and international growth. The company's goal of reaching cash flow breakeven by mid-2027 is also on track, with expansion of the customer pipeline to $127M. However, there are potential risks in the HCIT space, such as government program cuts and constrained hospital budgets, which could impact spending on HCIT. Additionally, increased competition and delays in purchasing decisions for non-EHR related solutions could also pose challenges for DarioHealth.

DarioHealth (DRIO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DarioHealth (DRIO) Forecast

Analysts have given DarioHealth (DRIO) a Buy based on their latest research and market trends.

According to 2 analysts, DarioHealth (DRIO) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DarioHealth (DRIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.